August 31, 2017
Congrats to Dr. Sherri McFarland and Dr. Colin Cameron!
From Dr. McFarland: “the photobiological activity of our lead photodynamic compound (PDC) in the bladder cancer trial has been computationally validated by a third-party, and that this platform has led us to create our new pipeline technology for brain and lung cancer, with the new PDC supercatalysts exhibiting unprecedented biological activity (killing cancer cells at femtomolar concentrations)”.
Please see the full official press release here.